Syros Pharmaceuticals Reports the P-III (SELECT-MDS-1) Study Data of Tamibarotene for Treating Myelodysplastic Syndrome
Shots:
- Syros Pharmaceuticals has reported the topline results from P-III (SELECT-MDS-1) clinical evaluation of tamibarotene (oral, selective, RARα agonist) for treating myelodysplastic syndrome (HR-MDS)
- The P-III (SELECT-MDS-1) study assessed the safety & efficacy of tamibarotene + azacitidine vs matching PBO among patients with HR-MDS having RARA overexpression. The 1EP was CR rate in the first 190 patients
- Study did not achieve its 1EP, depicting a CR rate of 23.8% (n=126) vs 18.8% (n=64) in the ITT population, that was not significant. In 245 patients analyzed for safety, the combination was generally well-tolerated with an adverse event profile similar to previous studies. Trial will be discontinued with data analysis underway to determine the next steps
Ref: Syros Pharmaceuticals | Image:Syros Pharmaceuticals
Related News:- AstraZeneca Provides Update on P-III (KOMET) Study of Koselugo for Treating Neurofibromatosis Type 1
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
